Choate Legal Podcasts

In this episode of Choate’s Intellectual Property Insights podcast, Charles Lyon, Margo Monroe, and Michael Schmitt continue their discussion on IP ownership and control in the context of IP due diligence, building on the foundational principles introduced in Part I of this series. As acquirers, investors, and licensees dig deeper into due diligence, understanding how intellectual property is owne...

In this episode of Choate’s Intellectual Property Insights podcast, Charles Lyon, Margo Monroe, and Michael Schmitt explore why understanding intellectual property (IP) ownership and control is essential in today’s fast‑paced business environment. For investors, acquirers, and licensees, a firm grasp of these fundamentals is critical to accurately assessing the value and security of IP assets duri...

In this episode of Choate's Intellectual Property Insights podcast, Michael Shinall, Melissa Adams, and Margo Monroe discuss IP due diligence from the perspective of potential investors, acquirers, and licensees. Topics will include how protection, ownership and control, and freedom to operate play a crucial role in the diligence process, as well as insights into risk mitigation and how to ef...

In this episode of the Examining Patents Podcast Series, Stephanie Schonewald and Michael Shinall discuss issues impacting compliance with Article 4 of the Paris Convention, a critical provision for establishing and maintaining the priority date of your patent application. We revisit how the provisions of Article 4 work, and how to avoid potential missteps that could lead to losing a priority clai...

In this episode of the Examining Patents Podcast Series, Rolando Medina and Dan Klein provide a detailed summary of the USPTO’s new fee requirement based on Information Disclosure Statement (IDS) size, which went into effect on January 19, 2025.

In this episode of Choate’s Examining Patents podcast series, Kristen Buteau and Stephanie Schonewald discuss obviousness-type double patenting (ODP) rejections issued by the USPTO based on the claims of later-filed, later-expiring unrelated patents and review a recent ex parte appeal case that addresses such rejections.

As the first installment of Choate’s Conducting Clinical Trials series, Bryana McGillycuddy and John Rearick discuss a range of implications associated with the timing of filing, including the validity of the patent and the risk of inadvertent disclosure.

Eric Marandett and Rolando Medina review Amgen v. Sanofi and discuss strategies for how to successfully describe, claim, and assert antibody patents in the evolving legal landscape.